---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-003241"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:29:40.064221+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential

## Summary
- BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.
- Final pre-clinical mouse model study expected H1 2025; IND filing planned by year-end.
- BP1001-A downregulates Grb2 expression to increase insulin sensitivity in muscle cells.
- CEO cites need for alternative glucose-lowering treatments in obese T2D patients.

## SEC filing metadata
- accession: 0001558370-25-003241
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/0001558370-25-003241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837025003241/bpth-20250318x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-003241
- JSON: https://secwatch.observer/filing/0001558370-25-003241.json
- Plain text: https://secwatch.observer/filing/0001558370-25-003241.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.